Research Article
Impact of Immunochemotherapy-Related Hepatic Toxicity on the Outcome of HCV-Positive Diffuse Large B-Cell Lymphoma Patients
Table 3
Hepatic toxicity in both groups.
| | | Grade | HCV positive
(group A; = 7) | HCV negative
(group B; = 21) | value |
| | ALT | G 0 | 1 (14.3%) | 9 (42.8%) | 0.15 | | G 1 | 4 (57.1%) | 11 (52.4%) | | G 2 | 2 (28.6%) | 1 (4.8%) |
| | AST | G 0 | 1 (14.3%) | 12 (57.1%) | 0.07 | | G 1 | 4 (57.1%) | 8 (38.1%) | | G 2 | 2 (28.6%) | 1 (4.8%) |
| | Bilirubin | G 0 | 5 (71.4%) | 21 (100%) | 0.06 | | G 1 | 1 (14.3%) | 0 (0%) | | G 2 | 1 (14.3%) | 0 (0%) |
| | INR | G 0 | 4 (57.1%) | 20 (95.2%) | 0.04* | | G 1 | 3 (42.9%) | 1 (4.8%) |
| | Albumin | G 0 | 6 (85.7%) | 21 (100%) | 0.25 | | G 1 | 0 (0%) | 0 (0%) | | G 2 | 1 (14.3%) | 0 (0%) |
| | Alkaline phosphatase | G 0 | 3 (42.9%) | 14 (66.7%) | 0.21 | | G 1 | 3 (42.9%) | 7 (33.3%) | | G 2 | 1 (14.3%) | 0 (0%) |
| | Hepatic failure# | G 0 | 6 (85.7%) | | 0.25 | | G 3 | 0 (0%) | | | G 4 | 1 (14.3%) | |
|
|
means significant ( < 0.05).
#means hepatic encephalopathy.
|
